bioRxiv ScienceSearch

Biology subjects

Meyerson, W.

Publications and source records attributed to Meyerson, W..

2 recordsLinked to original sources

Genomic variants concurrently listed in a somatic and a germline mutation database have implications for disease-variant discovery and genomic privacy

BackgroundMutations arise in the human genome in two major settings: the germline and soma. These settings involve different inheritance patterns, chromatin structures, and environmental exposures, all of which might be predicted to differentially affect the distribution of substitutions found in these settings. Nonetheless, recent studies have found that somatic and germline mutation rates are similarly affected by endogenous mutational processes and epigenetic factors.\n\nResultsHere, we quantified the number of single nucleotide variants that co-occur between somatic and germline call-sets (cSNVs), compared this quantity with expectations, and explained noted departures. We found that three times as many variants are shared between the soma and germline than is expected by independence. We developed a new, general-purpose statistical framework to explain the observed excess of cSNVs in terms of the varying mutation rates of different kinds substitution types and of genomic regions. Using this metric, we find that more than 90% of this excess can be explained by our observation that the basic substitution types (such as N[C->T]G, C->A, etc.) have correlated mutation rates in the germline and soma. Matched-normal read depth analysis suggests that an appreciable fraction of this excess may also derive from germline contamination of somatic samples.\n\nConclusionOverall, our results highlight the commonalities in substitution patterns between the germline and soma. The universality of some aspects of human mutation rates offers insight into the potential molecular mechanisms of human mutation. The highlighted similarities between somatic and germline mutation rates also lay the groundwork for future studies that distinguish disease-causing variants from a genomic background informed by both somatic and germline variant data. Moreover, our results also indicate that the depth of matched normal sequencing necessary to ensure genomic privacy of donors of somatic samples may be higher than previously appreciated. Furthermore, the fact that we were able to explain such a high portion of recurrent variants using known determinants of mutation rates is evidence that the genomics community has already discovered the most important predictors of mutation rates for single nucleotide variants.

genomics

Passenger mutations in 2500 cancer genomes: Overall molecular functional impact and consequences

The Pan-cancer Analysis of Whole Genomes (PCAWG) project provides an unprecedented opportunity to comprehensively characterize a vast set of uniformly annotated coding and non-coding mutations present in thousands of cancer genomes. Classical models of cancer progression posit that only a small number of these mutations strongly drive tumor progression and that the remaining ones (termed \"putative passengers\") are inconsequential for tumorigenesis. In this study, we leveraged the comprehensive variant data from PCAWG to ascertain the molecular functional impact of each variant. The impact distribution of PCAWG mutations shows that, in addition to high- and low-impact mutations, there is a group of medium-impact putative passengers predicted to influence gene activity. Moreover, the predicted impact relates to the underlying mutational signature: different signatures confer divergent impact, differentially affecting distinct regulatory subsystems and gene categories. We also find that impact varies based on subclonal architecture (i.e., early vs. late mutations) and can be related to patient survival. Finally, we note that insufficient power due to limited cohort sizes precludes identification of weak drivers using standard recurrence-based approaches. To address this, we adapted an additive effects model derived from complex trait studies to show that aggregating the impact of putative passenger variants (i.e. including yet undetected weak drivers) provides significant predictability for cancer phenotypes beyond the PCAWG identified driver mutations (12.5% additive variance). Furthermore, this framework allowed us to estimate the frequency of potential weak driver mutations in the subset of PCAWG samples lacking well-characterized driver alterations.

genomics